Organon & Co. Reports Q1 2026 Results and Announces Pending Acquisition by Sun Pharmaceutical Industries

Key Highlights from Organon’s First Quarter 2026 Report

• Q1 2026 Revenue: \$1.46 billion, representing a 4% decrease as-reported and a 9% decrease excluding the impact of foreign currency compared to Q1 2025.
• Diluted Earnings Per Share (EPS): \$0.55 (GAAP); Non-GAAP Adjusted diluted earnings per share were \$0.71.
• Net Income: \$146 million (up 68% YoY); Non-GAAP Adjusted Net Income was \$188 million (down 29% YoY).
• Adjusted EBITDA: \$415 million, with an Adjusted EBITDA margin of 28.4% (down from 32.0% in Q1 2025).
• Dividend Declared: Quarterly dividend of \$0.02 per share, payable June 11, 2026, to shareholders of record as of May 11, 2026.
• Cash and Debt Position: \$1.12 billion in cash and cash equivalents; \$8.57 billion in debt as of March 31, 2026.
• Pending Merger: Organon announced a definitive agreement for an all-cash merger into Sun Pharmaceutical Industries Limited, expected to close in early 2027, pending regulatory and shareholder approvals.
• No Forward Guidance: In light of the pending merger, Organon will not be providing financial guidance or hosting future quarterly earnings calls.

Segment Performance and Product Trends

Women’s Health

• Revenue: \$389 million, down 16% as-reported and 19% ex-FX YoY.
• Nexplanon/Implanon NXT: Sales fell 21% ex-FX (U.S. sales down 28%) due to lower physician demand after five-year label approval (delaying reinsertions) and ongoing uncertainty around federal funding. International sales declined 4% ex-FX, with Brazil a bright spot.
• Marvelon/Mercilon: Sales dropped 36% ex-FX, mainly due to decreased demand and market contraction in China and shipment timing in Asia Pacific.
• Global Fertility: Revenue dropped 9% ex-FX due to competition-driven price reductions in the U.S., partially offset by market growth in China.
• Jada System Divestiture: Sale completed in January 2026, reflected as a one-time gain.

Biosimilars

• Revenue: \$173 million, up 23% as-reported and 21% ex-FX YoY.
• Key Drivers: Strong performance of Hadlima (adalimumab-bwwd) in the U.S. and Puerto Rico, and contributions from new assets Bildyos (denosumab-nxxp), Bilprevda (denosumab-nxxp) approved by FDA in Q3 2025, and Tofidence (tocilizumab-bavi), acquired in Q2 2025.

Established Brands

• Revenue: \$880 million, down 1% as-reported and 7% ex-FX.
• Mixed Results: Emgality (galcanezumab-gnlm) contribution offset by declines in respiratory portfolio (notably Singulair), driven by pricing pressure and volume declines following guideline changes in China and other markets. Dulera sales also fell due to pricing and demand decreases in the U.S. VTAMA (tapinarof) grew modestly YoY.

Profitability and Margins

• Gross Profit: \$783 million (down 7% YoY); Non-GAAP adjusted gross profit \$861 million (down 8% YoY).
• Gross Margin: 53.6% (down from 55.6%); Non-GAAP adjusted gross margin 59.0% (down from 61.7%). Declines attributed to unfavorable pricing, product mix, and FX rates.
• Adjusted EBITDA Margin: 28.4% (down from 32.0%), primarily due to reduced gross margin.

Detailed Financial Tables and Regional Sales

• Sales by Geography:
  • Europe & Canada: \$412 million (up from \$376 million)
  • United States: \$358 million (down from \$412 million)
  • Asia Pacific & Japan: \$226 million (down from \$251 million)
  • China: \$194 million (down from \$204 million)
  • Latin America, Middle East, Russia, Africa: \$247 million (up from \$240 million)
• Sales by Top Products: Nexplanon/Implanon NXT (\$201M), Follistim AQ (\$61M), Hadlima (\$67M), Renflexis (\$57M), Zetia (\$87M), among others.

Price-Sensitive and Shareholder-Relevant Developments

• Pending Merger with Sun Pharma: The most significant, price-sensitive development is Organon’s announced all-cash merger with Sun Pharmaceutical Industries Limited, expected to close in early 2027. The transaction is subject to regulatory and shareholder approval, and no financial guidance will be given until close.
• Suspension of Guidance and Earnings Calls: Organon will not provide future financial guidance or host earnings calls during the pending acquisition period, which may affect transparency and investor sentiment.
• Dividend Continuation: The Board declared a quarterly dividend, signaling ongoing cash return to shareholders even in the midst of the merger process.
• Risks Highlighted: The company outlines multiple risks regarding the merger, including possible delays, failure to secure approvals, competing offers, regulatory hurdles, and potential impacts on staff and business relationships during the transition. These may all affect share value and require close monitoring by investors.
• Non-GAAP Adjustments and One-Time Items: Investors should note the impact of large one-time items (e.g., Jada divestiture gain) and ongoing restructuring, which significantly affect period-to-period comparability.

Key Takeaways for Investors

• While Organon’s core business experienced revenue declines and margin compression, biosimilars saw robust growth, and the company remains highly cash-generative.
• The pending Sun Pharma merger is the most critical development, likely to drive the stock in the coming quarters depending on regulatory progress and shareholder sentiment.
• Investors should be aware of the lack of future guidance and the risks associated with the transaction, as well as the company’s significant debt load.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All information is based on company-reported financial statements and may be subject to change or revision. Investors should consult the company’s SEC filings and their own financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that may impact actual results.

View Organon & Co. Historical chart here